Medical Communications

Shionogi’s antibacterial therapy Fetroja (cefiderocol) has secured approval in the US for the treatment of complicated urinary tract infections (cUTI), …

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted in favour of expanding the existing approval of Irish …

As we close in on the weekend, it’s been a week characterised by data reveals and crucial marketing approvals, including …

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …

A new report released on World Diabetes Day has shone a light on a startling lack of knowledge surrounding type …

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, who in her new role …

After more than two decades at the head of the company, it has emerged that Miles D White (pictured, right) …

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to step down from the role …

You studied biology at Liverpool John Moores University before heading straight to GSK in 1990 as a Sales Representative; was …

Pfizer and Merck KGaA’s EMD Serono have lifted the lid on new Phase 3 data for Bavencio (avelumab) in the …

In our rundown of the week’s most popular stories, President Donald Trump has named his first choice for the top …

Roche has revealed its decision to terminate further development of its anti-myostatin adnectin protein agent RG6206 after it became apparent …

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

Takeda has revealed strong new findings for Ninlaro (ixazomib), confirming that the therapy met its primary endpoint as a first-line …

Endo International has announced its “CEO succession plan”, revealing that the company’s Chief Executive and President Paul V Campanelli has …